Stock listing

Lang & Schwarz:A1JH3B Egetis Therapeutics AB Aktie

German listing (Lang & Schwarz) of Egetis Therapeutics AB · home listing Stockholm:EGTX

Follow Egetis Therapeutics AB into a list and get an email when it puts out news.

Home listing price · OMXSTO:EGTX

9.07 SEK -0.17 (-1.8%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXSTO:EGTX

Past 3 months +53.2% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
9.00 – 9.36 SEKOct 19, 2026
Volume
2.04M sharesOct 19, 2026
Market cap
4.22B SEKAt the close on Oct 19, 2026 · price × 465.0M shares outstanding
Egetis Therapeutics AB logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Stockholm:EGTX · Home9.07 SEK-0.17 (-1.8%)2,038,5109.269.369.009.24Close on Oct 19, 2026
LSE:0ABW9.11 SEK-0.285 (-3.0%)174,2429.249.249.039.395Close on Oct 19, 2026
Frankfurt:P0F€0.80 EUR+0.005 (+0.6%)—€0.80€0.80€0.80€0.795Close on Oct 19, 2026

Daily closes

Last 3 months, Jul 20, 2026 – Oct 19, 2026 · OMXSTO:EGTX · SEK, adjusted for splits

DayCloseChange%OpenHighLowVolume
9.07-0.17-1.8%9.269.369.002,038,510
9.24+0.03+0.3%9.219.459.211,059,057
9.21-0.24-2.5%9.509.539.112,009,983
9.45-0.15-1.6%9.639.679.302,042,968
9.60-0.35-3.5%9.9010.069.602,244,713
9.95+0.02+0.2%9.9210.109.801,980,498
9.93+0.08+0.8%9.9710.089.752,212,439
9.85+0.31+3.2%9.6610.149.454,254,187
9.54-0.02-0.2%9.359.789.254,158,483
9.56+0.50+5.5%9.159.619.134,008,629
9.06-0.12-1.3%9.189.388.953,737,929
9.18-0.26-2.8%9.459.689.146,060,584
9.44+0.58+6.5%8.889.478.819,704,484
8.86+0.43+5.1%8.549.108.448,160,852
8.43+0.99+13.3%8.479.098.2230,201,271
7.44-0.44-5.6%7.918.007.362,232,918
7.88+0.17+2.2%7.727.997.542,378,572
7.71-0.08-1.0%7.807.957.591,122,836
7.79-0.15-1.9%7.947.957.65659,437
7.94+0.34+4.5%7.647.967.60854,144
7.60-0.31-3.9%8.008.007.432,254,925
7.91-0.09-1.1%8.048.307.901,826,613
8.00+0.12+1.5%7.948.047.87508,682
7.88+0.01+0.1%7.927.957.80529,098
7.87-0.09-1.1%7.968.187.87689,813
7.96+0.07+0.9%8.008.047.89524,614
7.89-0.16-2.0%8.078.107.87505,531
8.05-0.01-0.1%8.008.207.951,173,584
8.06+0.07+0.9%7.988.067.90811,835
7.99+0.34+4.4%7.557.997.55919,513
7.65-0.05-0.6%7.737.827.50717,128
7.70-0.14-1.8%7.907.977.62636,574
7.84+0.07+0.9%7.828.057.82567,811
7.77-0.12-1.5%7.908.067.75558,715
7.89+0.04+0.5%7.868.047.71957,098
7.85-0.15-1.9%8.088.207.851,012,317
8.00-0.04-0.5%8.038.147.94904,285
8.04+0.04+0.5%7.958.047.451,143,835
8.00+0.13+1.7%7.868.157.731,317,378
7.87+0.36+4.8%7.497.877.451,437,262
7.51+0.18+2.5%7.357.647.201,225,791
7.33+0.53+7.8%6.967.376.961,515,701
6.80-0.14-2.0%7.007.006.73574,661
6.94-0.08-1.1%7.007.156.91580,491
7.02-0.07-1.0%7.037.126.91512,294
7.09-0.07-1.0%7.207.207.01433,837
7.16-0.08-1.1%7.197.287.00661,887
7.24+0.01+0.1%7.157.357.12499,041
7.23+0.29+4.2%6.947.266.92695,576
6.94-0.05-0.7%7.067.076.93340,386
6.99-0.09-1.3%7.087.146.731,121,387
7.08+0.23+3.4%6.847.216.841,256,588
6.85+0.11+1.6%6.846.946.67731,610
6.74+0.36+5.6%6.496.906.39803,369
6.38+0.27+4.4%6.196.536.08844,845
6.11+0.11+1.8%6.076.325.861,827,310
6.00-0.11-1.8%6.116.285.991,362,958
6.11-0.15-2.4%6.256.256.01601,757
6.26-0.32-4.9%6.586.606.22586,322
6.58-0.14-2.1%6.736.736.56261,578
6.720.000.0%6.836.836.62304,162
6.72+0.08+1.2%6.646.866.63584,973
6.64-0.02-0.3%6.696.706.54379,923
6.66+0.31+4.9%6.346.736.28690,239
6.35-0.02-0.3%6.426.496.21350,221
6.37+0.17+2.7%6.276.756.26979,143
Ticker
Lang & Schwarz:A1JH3B
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Calls

Replays

  • Egetis Therapeutics (Stockholm:EGTX) Q2 2026 Earnings Call

    Fri, Aug 21, 2026 · 8:00 AM ET

    Watch Transcript

  • Egetis Therapeutics (Stockholm:EGTX) Q1 2026 Earnings Call

    Wed, Apr 29, 2026 · 4:00 AM ET

    Watch Transcript

Latest news

Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE(R) (tiratricol) for Patients with MCT8 Deficiency

Sep 29, 2026

Closed 8.43 (+13.3%) on Sep 29, 2026

Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with MCT8 Deficiency

Sep 28, 2026

Closed 8.43 (+13.3%) on Sep 29, 2026

Egetis Therapeutics to Participate in Upcoming Investor Conferences in September

Sep 3, 2026

Closed 7.84 (+0.9%) on Sep 3, 2026

Egetis' Interim report Q2 2026

Aug 21, 2026

Closed 7.33 (+7.8%) on Aug 21, 2026

Invitation to Presentation of Egetis’ Q2 2026 Report on August 21, 2026

Aug 7, 2026

Closed 7.08 (+3.4%) on Aug 7, 2026

Change in the number of shares and votes in Egetis Therapeutics

May 29, 2026

Exercise of options under employee stock option program and notification of insider trading

May 13, 2026

Egetis Announces Grant of Patent for MCT8 Deficiency Composition in The U.S.

May 5, 2026

Interim ReportQ12026

May 3, 2026

Invitation to Presentation of Egetis’ First Quarter 2026 Report on April 29, 2026

Apr 24, 2026

All Egetis Therapeutics AB news

Decks

Egetis Therapeutics AB on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
18 in the last 12 months · 18 in all · newest Sep 29, 2026 · oldest 2026
Calls
2 calls with a replay · 2 with a transcript · latest Aug 21, 2026
Decks
10 decks · latest Aug 21, 2026

Where Egetis Therapeutics AB is listed

ListingExchangeCountryCurrency
Stockholm:EGTX · Home listingStockholmSwedenSEK
LSE:0ABWLSEUnited KingdomSEK
OTC:PDPHFOTCUnited StatesUSD
Lang & Schwarz:A1JH3B · This pageLang & SchwarzGermanyEUR
LS Exchange:A1JH3BLS ExchangeGermanyEUR
Frankfurt:P0FFrankfurtGermanyEUR
Aquis:EGTXSAquisUnited KingdomSEK
gettex:P0FgettexGermanyEUR
Aquis:EGTXSAquisUnited KingdomSEK
Munich:P0FMunichGermanyEUR
Stuttgart:P0FStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Egetis Therapeutics AB.